RESUMEN
Indian shad, Tenualosa ilisha, is a commercially important anadromous fish representing major catch in Indo-pacific region. The present study evaluated partial Cytochrome b (Cyt b) gene sequence of mtDNA in T. ilisha for determining genetic variation from Bay of Bengal and Arabian Sea origins. The genomic DNA extracted from T. ilisha samples representing two distant rivers in the Indian subcontinent, the Bhagirathi (lower stretch of Ganges) and the Tapi was analyzed. Sequencing of 307 bp mtDNA Cytochrome b gene fragment revealed the presence of 5 haplotypes, with high haplotype diversity (Hd) of 0.9048 with variance 0.103 and low nucleotide diversity (π) of 0.14301. Three population specific haplotypes were observed in river Ganga and two haplotypes in river Tapi. Neighbour-joining tree based on Cytochrome b gene sequences of T. ilisha showed that population from Bay of Bengal and Arabian Sea origins belonged to two distinct clusters.
Asunto(s)
ADN Mitocondrial/genética , Peces/genética , Variación Genética , Animales , FilogeniaRESUMEN
The beneficial effects of elevated CO2 on plants are expected to be compromised by the negative effects posed by other global changes. However, little is known about ozone (O3)-induced modulation of elevated CO2 response in plants with differential sensitivity to O3. An old (Triticum aestivum cv. Beijing 6, O3 tolerant) and a modern (T. aestivum cv. Zhongmai 9, O3 sensitive) winter wheat cultivar were exposed to elevated CO2 (714 ppm) and/or O3 (72 ppb, for 7h d(-1)) in open-topped chambers for 21 d. Plant responses to treatments were assessed by visible leaf symptoms, simultaneous measurements of gas exchange and chlorophyll a fluorescence, in vivo biochemical properties, and growth. It was found that elevated CO2 resulted in higher growth stimulation in the modern cultivar attributed to a higher energy capture and electron transport rate compared with the old cultivar. Exposure to O3 caused a greater growth reduction in the modern cultivar due to higher O3 uptake and a greater loss of photosystem II efficiency (mature leaf) and mesophyll cell activity (young leaf) than in the old cultivar. Elevated CO2 completely protected both cultivars against the deleterious effects of O3 under elevated CO2 and O3. The modern cultivar showed a greater relative loss of elevated CO2-induced growth stimulation due to higher O3 uptake and greater O3-induced photoinhibition than the old cultivar at elevated CO2 and O3. Our findings suggest that the elevated CO2-induced growth stimulation in the modern cultivar attributed to higher energy capture and electron transport rate can be compromised by its higher O3 uptake and greater O3-induced photoinhibition under elevated CO2 and O3 exposure.
Asunto(s)
Dióxido de Carbono/metabolismo , Ozono/metabolismo , Fotosíntesis , Triticum/crecimiento & desarrollo , Clorofila/análisis , Clorofila/metabolismo , Clorofila A , Transporte de Electrón , Metabolismo Energético , Células del Mesófilo/metabolismo , Procesos Fotoquímicos , Complejo de Proteína del Fotosistema II/metabolismo , Enfermedades de las Plantas , Hojas de la Planta/metabolismo , Especificidad de la Especie , Factores de TiempoRESUMEN
Recent reports challenge the widely accepted idea that drought may offer protection against ozone (O(3)) damage in plants. However, little is known about the impact of drought on the magnitude of O(3) tolerance in winter wheat species. Two winter wheat species with contrasting sensitivity to O(3) (O(3) tolerant, primitive wheat, T. turgidum ssp. durum; O(3) sensitive, modern wheat, T. aestivum L. cv. Xiaoyan 22) were exposed to O(3) (83ppb O(3), 7h d(-1)) and/or drought (42% soil water capacity) from flowering to grain maturity to assess drought-induced modulation of O(3) tolerance. Plant responses to stress treatments were assessed by determining in vivo biochemical parameters, gas exchange, chlorophyll a fluorescence, and grain yield. The primitive wheat demonstrated higher O(3) tolerance than the modern species, with the latter exhibiting higher drought tolerance than the former. This suggested that there was no cross-tolerance of the two stresses when applied separately in these species/cultivars of winter wheat. The primitive wheat lost O(3) tolerance, while the modern species showed improved tolerance to O(3) under combined drought and O(3) exposure. This indicated the existence of differential behaviour of the two wheat species between a single stress and the combination of the two stresses. The observed O(3) tolerance in the two wheat species was related to their magnitude of drought tolerance under a combination of drought and O(3) exposure. The results clearly demonstrate that O(3) tolerance of a drought-sensitive winter wheat species can be completely lost under combined drought and O(3) exposure.
Asunto(s)
Adaptación Fisiológica/efectos de los fármacos , Sequías , Ozono/farmacología , Estaciones del Año , Triticum/efectos de los fármacos , Triticum/fisiología , Análisis de Varianza , Transporte de Electrón/efectos de los fármacos , Fotones , Fotosíntesis/efectos de los fármacos , Complejo de Proteína del Fotosistema II/metabolismo , Estomas de Plantas/efectos de los fármacos , Estomas de Plantas/fisiología , Triticum/crecimiento & desarrolloRESUMEN
Modern wheat (Triticum aestivum L.) is one of the most ozone (O(3))-sensitive crops. However, little is known about its genetic background of O(3) sensitivity, which is fundamental for breeding O(3)-resistant cultivars. Wild and cultivated species of winter wheat including donors of the A, B and D genomes of T. aestivum were exposed to 100 ppb O(3) or charcoal-filtered air in open top chambers for 21 d. Responses to O(3) were assessed by visible O(3) injury, gas exchange, chlorophyll fluorescence, relative growth rate, and biomass accumulation. Ozone significantly decreased light-saturated net photosynthetic rate (-37%) and instantaneous transpiration efficiency (-42%), but increased stomatal conductance (+11%) and intercellular CO(2) concentration (+11%). Elevated O(3) depressed ground fluorescence (-8%), maximum fluorescence (-26%), variable fluorescence (-31%), and maximum photochemical efficiency (-7%). Ozone also decreased relative growth rate and the allometric coefficient, which finally reduced total biomass accumulation (-54%), but to a greater extent in roots (-77%) than in the shoot (-44%). Winter wheat exhibited significant interspecies variation in the impacts of elevated O(3) on photosynthesis and growth. Primitive cultivated wheat demonstrated the highest relative O(3) tolerance followed by modern wheat and wild wheat showed the lowest. Among the genome donors of modern wheat, Aegilops tauschii (DD) behaved as the most O(3)-sensitive followed by T. monococcum (AA) and Triticum turgidum ssp. durum (AABB) appeared to be the most O(3)-tolerant. It was concluded that the higher O(3) sensitivity of modern wheat was attributed to the increased O(3) sensitivity of Aegilops tauschii (DD), but not to Triticum turgidum ssp. durum (AABB) during speciation.
Asunto(s)
Ozono/toxicidad , Triticum/efectos de los fármacos , Triticum/genética , Clorofila/metabolismo , Hojas de la Planta/efectos de los fármacos , Hojas de la Planta/metabolismo , Transpiración de Plantas/efectos de los fármacos , Especificidad de la EspecieRESUMEN
BACKGROUND AND AIMS: New maize (Zea mays) hybrids outperformed old ones even at reduced N rates. Understanding the mechanisms of the differences in performance between newer and older hybrids under N deficiency could provide avenues for breeding maize cultivars with large yield under N deficiency, and reduce environmental pollution caused by N fertilizers. METHODS: N deficiency effects on grain weight, plant weight, harvest index, leaf area and photosynthetic traits were studied in the field for six maize hybrids released during the past 50 years to compare their tolerance and to explore their physiological mechanisms. KEY RESULTS: N deficiency decreased grain yield and plant weight in all hybrids, especially in the older hybrids. However, there was no significant difference in harvest index, rate of light-saturated photosynthesis (Psat) 20 d before flowering, leaf area or plant weight at flowering between the N-deficient and control plants of all hybrids. Dry matter production after flowering of the N-deficient plants was significantly lower than that of the control plants in all hybrids, especially in the older hybrids, and was mostly due to differences in the rate of decrease in photosynthetic capacity during this stage. The lower Psat of the older hybrids was not due to stomatal limitation, as there was no significant difference in stomatal conductance (gs) and intercellular CO2 concentration (Ci) between the hybrids. N deficiency accelerated senescence, i.e. decreased chlorophyll and soluble protein contents, after anthesis more for the earlier released hybrids than for the later ones. N deficiency decreased phosphoenolpyruvate carboxylase (PEPCase) activity significantly more in older hybrids than newer hybrids, and affected the maximal efficiency of PSII photochemistry (Fv/Fm) only in the old hybrids and at the late stage. CONCLUSIONS: Compared with older (earlier released) hybrids, newer (later released) hybrids maintained greater plant and grain weight under N deficiency because their photosynthetic capacity decreased more slowly after anthesis, associated with smaller non-stomatal limitations due to maintenance of PEPCase activity, and chlorophyll and soluble protein content.
Asunto(s)
Hibridación Genética , Nitrógeno/deficiencia , Fotosíntesis/fisiología , Zea mays/metabolismo , Dióxido de Carbono/metabolismo , Clorofila/metabolismo , Cruzamientos Genéticos , Flores/fisiología , Luz , Nitrógeno/metabolismo , Proteínas de Plantas/metabolismo , Factores de Tiempo , Zea mays/genéticaRESUMEN
Critical processes underlying cancers must be better understood to develop strategies for treatment and prevention. A chemotherapeutic strategy is proposed that is based upon re-establishment, with a drug, of nullified programmed cell death (apoptosis) in cancer cells, which to survive have mutated to block apoptosis. A chemotherapy that is specific against tumors implanted in mice demonstrated the feasibility of this principle. This therapy is specific because it affects a process unique to cancer cells. It also has the advantage of killing these cells, in contrast to reversibly blocking their proliferation. The anti-apoptotic transcription factor NF-kappaB provides a potential therapeutic target in estrogen receptor negative (ER-) breast cancers that over-express the epidermal growth factor family of receptors (EGFR). Further investigations of the pathways utilize dominant negative protein inhibitory peptide, and small inhibitory RNAs (siRNAs) to block the production of relevant enzymes.
Asunto(s)
Apoptosis , FN-kappa B/antagonistas & inhibidores , Neoplasias/patología , Animales , Antineoplásicos/farmacología , Humanos , Neoplasias/tratamiento farmacológico , ARN Interferente Pequeño/fisiologíaRESUMEN
Cyclin E1 (formerly called cyclin E) and the recently described cyclin E2 belong to the family of E-type cyclins that operate during the G(1)/S phase progression in mammalian cells. The two E-cyclins share a catalytic partner, cyclin-dependent kinase 2 (CDK2), and activate their associated kinase activities at similar times during cell cycle progression. Despite these similarities, it is unknown whether the two proteins perform distinct functions, or, alternatively, they control S-phase entry of different cell types in a tissue-specific fashion. To start addressing in vivo functions of E-cyclins, we determined the expression pattern of cyclins E1 and E2 during normal mouse development. We found that the two E-cyclins showed very similar patterns of expression; both were expressed within the proliferating compartment during embryo development. Analyses of cells and tissues lacking members of the retinoblastoma (pRB) family of proteins revealed that the expression of both cyclins is controlled in a pRB-dependent, but p107- and p130-independent fashion, likely through the pRB-dependent E2F transcription factors. We also found that cyclins E1 and E2 are expressed at high levels in mouse breast tumors driven by the Myc oncogene. Last, we found that cyclin E2 is overexpressed in approximately 24% of analyzed human mammary carcinomas. Collectively these findings suggest that the expression of cyclins E1 and E2 is governed by similar molecular circuitry.
Asunto(s)
Neoplasias de la Mama/genética , Ciclina E/genética , Regulación del Desarrollo de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Animales , Northern Blotting , Embrión de Mamíferos/metabolismo , Desarrollo Embrionario y Fetal/genética , Regulación del Desarrollo de la Expresión Génica/fisiología , Regulación Neoplásica de la Expresión Génica/fisiología , Humanos , Ratones , Proteína de Retinoblastoma/fisiología , Células Madre/metabolismoRESUMEN
The effect of a kinase inhibitor Go6796 on growth of epidermal growth factor (EGF)-stimulated estrogen receptor negative (ER-) breast cancer cells in vivo and role of nuclear factor kappa B (NF-kappaB) on tumorogenesis have been investigated. This was studied in an animal model by implanting ER- mouse mammary epithelial tumor cells (CSMLO) in syngeneic A-J mice. (i) Local administration of Go6976 an inhibitor of protein kinases C alpha and beta inhibited growth of tumors and caused extensive necrotic degeneration and regression of the tumors without causing any microscopically detectable damage to the vital organs liver and lung. (ii) Stable expression of dominant-negative mutants of the beta subunit (dnIkkbeta) of the inhibitory kappa B (IkappaB) kinase (dnIkk) that selectively blocked activation of NF-kappaB caused loss of tumorigenic potential of CSMLO cells. Stable expression of dnIkkbeta also blocked phorbol 12-myristate 13-acetate (PMA)-induced activation of NF-kappaB and overexpression of cyclin D1, concomitantly with the loss or reduced tumorigenic potential of these cells. Thus, results from in vivo and in vitro experiments strongly suggest the involvement of NF-kappaB in ER- mammary epithelial cell-mediated tumorigenesis. We propose that blocking NF-kappaB activation not only inhibits cell proliferation, but also antagonizes the antiapoptotic role of this transcription factor in ER- breast cancer cells. Thus, NF-kappaB is a potential target for therapy of EGFR family receptor-overexpressing ER- breast cancers.
Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , FN-kappa B/antagonistas & inhibidores , Receptores de Estrógenos/metabolismo , Animales , Secuencia de Bases , Neoplasias de la Mama/genética , Carbazoles/farmacología , División Celular/efectos de los fármacos , Ciclina D1/metabolismo , Cartilla de ADN/genética , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Quinasa I-kappa B , Indoles/farmacología , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neoplasias Mamarias Experimentales/genética , Neoplasias Mamarias Experimentales/metabolismo , Neoplasias Mamarias Experimentales/patología , Ratones , Ratones Endogámicos A , Mutación , FN-kappa B/metabolismo , Proteína Quinasa C/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/genética , Proteínas Serina-Treonina Quinasas/metabolismo , Acetato de Tetradecanoilforbol/farmacología , Transfección , Células Tumorales CultivadasRESUMEN
BACKGROUND: The action of the steroid hormone estradiol (E2) is mediated via interaction with a specific receptor (ER) that initiates a series of events downstream, leading to the modulation of hormone-responsive genes and cell proliferation. Antihormones also bind, but do not confer the active configuration to ER, thereby, blocking the transmission of E2-ER-initiated signals for cell proliferation. Although these compounds qualify for successful therapy of ER-positive [ER (+)] breast cancer patients, only a fraction of patients responds to antihormone treatment. In this study, the functional status of ER is determined to identify alternative targets for therapy of antihormone-resistant ER (+) breast cancers. METHOD: The interaction of ER with a specific DNA sequence, designated as E2 response element (ERE), was targeted to assess the functional state of ER. ER-ERE complex formation was measured by electrophoretic mobility shift assay (EMSA) and by a newly developed technique, based on the preferential binding of DNA-protein complex to a nitrocellulose membrane (NMBA) that measures both total and functional fraction of ER. RESULTS: The NMBA assay identified functional variants of ER among ER (+) breast cancer cell lines and breast tumor biopsy specimens. ER of (21PT) cells did not bind E2 and these cells were tamoxifen (TAM) resistant. However 21PT cells were sensitive to a calmodulin (CaM) antagonist, W7, that blocked ERE-ER complex formation. CONCLUSIONS: ER variants of the 21PT type were detected among breast cancer biopsy specimens, emphasizing the significance of an alternative therapeutic target for TAM-resistant ER (+) human breast cancers with compounds such as W7.
Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Receptores de Estrógenos/metabolismo , Elementos de Respuesta/efectos de los fármacos , Adulto , Anciano , Bioquímica/métodos , Biopsia , Calmodulina/antagonistas & inhibidores , Colodión/metabolismo , Resistencia a Antineoplásicos , Inhibidores Enzimáticos/farmacología , Estradiol/metabolismo , Femenino , Hormonas/farmacología , Humanos , Persona de Mediana Edad , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Receptores de Progesterona/metabolismo , Sulfonamidas/farmacología , Tamoxifeno/farmacología , Resultado del Tratamiento , Células Tumorales CultivadasRESUMEN
The level of estrogen receptor (ER) is a key determinant for the management of ER-positive [ER(+)] breast cancer patients. Growth of many human breast cancers is regulated by estrogen (E2) and progesterone (Pr). Generally, the ER in ER(+) breast cancer patients is targeted for therapy with antihormones. However 40% of ER(+) patients do not respond to antihormone therapy. Thus, the identification of antihormone resistant ER(+) breast cancers is essential for therapeutic predictions. Although 3H-E2 binding and immunodetection can identify ER, these procedures do not assess the functional state of the receptor molecule. In this study we describe a novel and rapid assay for the detection of ER and its functional state on the basis of the downstream interaction with its response element (ERE) based on the preferential binding of DNA-protein complex (ERE-ER) to a nitrocellulose membrane (NMBA). This method permits measurement of both the total and the functional fraction of ER. The ER status was examined in breast cancer cell lines and in breast cancer biopsy specimens by (i) 3H-E2 binding assay, (ii) immunodetection assays and (iii) by its interaction with 32P-ERE. The sensitive NMBA assay was validated with well-characterized ER(+) breast cancer cell lines and also identified functional variants of ER among breast tumor biopsy specimens.
Asunto(s)
Neoplasias de la Mama/metabolismo , Receptores de Estrógenos/metabolismo , Biopsia , Neoplasias de la Mama/clasificación , Neoplasias de la Mama/genética , Colodión/metabolismo , ADN/genética , ADN/metabolismo , Proteínas de Unión al ADN/metabolismo , Estrógenos/metabolismo , Femenino , Humanos , Inmunoensayo/métodos , Ligandos , Proteínas de Neoplasias/metabolismo , Unión Proteica , Isoformas de Proteínas/metabolismo , Elementos de Respuesta/genética , Células Tumorales CultivadasRESUMEN
The epidermal growth factor (EGF) family of receptors (EGFR) is overproduced in estrogen receptor (ER) negative (-) breast cancer cells. An inverse correlation of the level of EGFR and ER is observed between ER- and ER positive (+) breast cancer cells. A comparative study with EGFR-overproducing ER- and low-level producing ER+ breast cancer cells suggests that EGF is a major growth-stimulating factor for ER- cells. An outline of the pathway for the EGF-induced enhanced proliferation of ER- human breast cancer cells is proposed. The transmission of mitogenic signal induced by EGF-EGFR interaction is mediated via activation of nuclear factor kappaB (NF-kappaB). The basal level of active NF-kappaB in ER- cells is elevated by EGF and inhibited by anti-EGFR antibody (EGFR-Ab), thus qualifying EGF as a NF-kappaB activation factor. NF-kappaB transactivates the cell-cycle regulatory protein, cyclin D1, which causes increased phosphorylation of retinoblastoma protein, more strongly in ER- cells. An inhibitor of phosphatidylinositol 3 kinase, Ly294-002, blocked this event, suggesting a role of the former in the activation of NF-kappaB by EGF. Go6976, a well-characterized NF-kappaB inhibitor, blocked EGF-induced NF-kappaB activation and up-regulation of cell-cycle regulatory proteins. This low molecular weight compound also caused apoptotic death, predominantly more in ER- cells. Thus Go6976 and similar NF-kappaB inhibitors are potentially novel low molecular weight therapeutic agents for treatment of ER- breast cancer patients.
Asunto(s)
Neoplasias de la Mama/metabolismo , Factor de Crecimiento Epidérmico/metabolismo , FN-kappa B/metabolismo , Receptores de Estrógenos/metabolismo , Transducción de Señal , Carbazoles/farmacología , Ciclo Celular , Ciclina D1/metabolismo , Ciclina D1/fisiología , Factor de Crecimiento Epidérmico/farmacología , Receptores ErbB/metabolismo , Femenino , Humanos , Indoles/farmacología , Cinética , FN-kappa B/antagonistas & inhibidores , Células Tumorales CultivadasRESUMEN
Calmodulin (CaM) has been reported to have affinity for the estrogen receptor (ER). Observations reported here reveal a direct physical interaction between purified CaM and ER. This direct ER-CaM interaction may be an initial event preceding the assembly of ER plus auxiliary proteins into the active ER complex with its DNA motif, the estrogen response element. We demonstrate that CaM is an integral component of this complex by using a system reconstituted from purified ER and nuclear extract from ER-negative breast cancer cells and also with ER-depleted nuclear extract of an ER-positive breast cancer cell line. Although CaM is essential for formation of this complex, it is not sufficient, suggesting roles also of auxiliary proteins. CaM also is functionally required for activation of an ER-responsive promoter, in the 17beta-estradiol-ER pathway of hormone action and regulation of 17beta-estradiol-responsive gene expression that is associated with proliferation of mammary epithelial cells.
Asunto(s)
Calmodulina/metabolismo , Regiones Promotoras Genéticas , Receptores de Estrógenos/metabolismo , Secuencia de Bases , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Núcleo Celular/metabolismo , ADN , Humanos , Pruebas de Precipitina , Unión Proteica , Receptores de Estrógenos/genética , Activación Transcripcional , Células Tumorales CultivadasRESUMEN
The small molecule S9a was derived from an established tumor necrosis factor-alpha (TNF-alpha) inhibitor (Canventol) by replacement of the isopropylidine group with a phenyl ring. S9a at 10 to 100 nM inhibited HIV production as potently as 3'-azido-3'-deoxythymidine (AZT), an inhibitor of viral reverse transcriptase. Furthermore, S9a and AZT in combination, at noncytoxic concentrations strongly inhibited HIV-1 replication that was more than additive and substantially prolonged the appearance of virus both in acutely infected CD4+ lymphocytes (SupT) in culture and in peripheral blood mononuclear cells (PBMCs) infected with a primary HIV-1 isolate. S9a inhibited TNF-alpha promoter-driven reporter gene activity. It was proposed that the mechanism of antiviral action of S9a was on the host cell, by blocking TNF-alpha transcription via a Tat-induced tar-independent loop, which decreases downstream NF-kappaB activation of HIV-1 long terminal repeat (LTR). S9a was superior to the first generation compound Canventol, which was superior to the natural compound sarcophytol A, demonstrating that further structure-based enhancement of potency of these compounds is feasible. This study suggests a therapeutic approach against AIDS by application of two drugs, one against a cellular and the other a viral target, which may provide an approach to the problem of frequent emergence of resistant variants to combinations of drugs that target only HIV genes.
Asunto(s)
Fármacos Anti-VIH/farmacología , Anticarcinógenos/farmacología , Ciclohexanoles/farmacología , VIH-1/efectos de los fármacos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Replicación Viral/efectos de los fármacos , Zidovudina/farmacología , Anticarcinógenos/química , Antineoplásicos/farmacología , Linfocitos T CD4-Positivos/virología , Línea Celular , Ciclohexanoles/química , Diterpenos/química , Diterpenos/farmacología , Combinación de Medicamentos , Sinergismo Farmacológico , Productos del Gen tat/antagonistas & inhibidores , VIH-1/genética , VIH-1/fisiología , Humanos , Células Jurkat/virología , FN-kappa B/antagonistas & inhibidores , Secuencias Repetitivas de Ácidos Nucleicos/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa/farmacología , Transfección , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
BACKGROUND: The receptor (ER) for estrogen (E2) is routinely assayed as a marker to determine the feasibility of anti-hormone therapy against breast cancer because ER-positive (ER+) tumors are much more likely to respond to anti-hormone therapy than are ER-negative (ER-). However 40% of ER+ breast cancer patients do not respond to anti-hormone therapy. We suggest that this unpredictability of therapeutic responses lies in the current ER assays, which measure only an initial component of the E2-responsive pathway, and that the difference depends upon altered downstream processes. We propose a functional criterion that subclassifies breast cancers on the basis of specific binding of ER to its cognate DNA sequence, the estrogen response element (ERE). MATERIALS AND METHODS: ER was identified in breast cancer cell lines by immunofluorescence assay, Western blot analysis, identification of ER-specific mRNA, and by interaction of the ER-ERE complex with three different ER-specific antibodies. ER-ERE complex formation was measured by electrophoretic mobility shift assay (EMSA). Transactivation of the E2-responsive gene was studied by transfection of cells with fusion gene construct with the promoter-containing ERE sequence and assay of reporter gene activity in the cell extracts. RESULTS: The growth of ER+ T47D cells was sensitive to tamoxifen, ICI-182,780, and ethynyl estradiol (EE2), whereas another ER+ breast cancer cell line, 21 PT, was resistant to these compounds. The estrogen receptor (ER) in the nuclear extracts of MCF-7 and T47D demonstrated hormone-dependent interaction with the response element (ERE) and also downstream transactivation of the E2-responsive PS2 promoter. But in the 21 PT cell line that was designated as ER- on the basis of ligand-binding assay and was found to be ER+ by all the other ER assays, ER-ERE interaction and PS2 promoter transactivation were independent of hormone. CONCLUSIONS: On the basis of the downstream functional assay of ER interaction with ERE, ER+ breast tumor cells can be subclassified into two categories. The first is E2-dependent (ERd+) and these cells should respond to anti-hormone therapy. The second type of ER interacts with ERE independent of E2 (ERi+) and constitutively transactivates responsive genes. It is predicted that the latter type of breast cancers will not respond to antihormone therapy.
Asunto(s)
Neoplasias de la Mama/clasificación , Receptores de Estrógenos/análisis , Secuencias Reguladoras de Ácidos Nucleicos , Anticuerpos Monoclonales , Antineoplásicos Hormonales/farmacología , Northern Blotting , Western Blotting , Neoplasias de la Mama/química , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Supervivencia Celular , Proteínas de Unión al ADN/análisis , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Estradiol/análogos & derivados , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Femenino , Fulvestrant , Humanos , Regiones Promotoras Genéticas , Receptores de Estrógenos/genética , Receptores de Estrógenos/metabolismo , Tamoxifeno/farmacología , Activación Transcripcional , Transfección , Células Tumorales CultivadasRESUMEN
The concept of environmental auditing in industrial units in India was formally introduced in March 1992 with the overall objective minimising consumption of resources and promoting use of clean technologies in industrial production to minimise generation of wastes. A series of discussions were held among the concerned regulatory agencies before and after making environmental auditing and submission of Annual Environmental Statements, a mandatory requirement for the industries. This followed organisation of a number of workshops, seminars and training programmers all over the country by different agencies dealing with environment protection, conducting of audit studies in 125 selected polluting industries in the country by the Central Pollution Control Board (CPCB), Delhi, and a number of other activities. The present paper gives the details of the activities before and after the introduction of this requirement in the country. The aspects covered include (i) the evolution of the concept, (ii) the history of the introduction of the scheme in the country and the organisational structure, (iii) the mandatory requirement and its applicability, (iv) the implementing agencies and their responsibilities, (v) summary of the training programmes/workshops organised in the country, (vi) case studies conducted by CPCB in selected polluting industries and the major findings, (vii) development of guidelines for conducting environmental audit in different categories of polluting industries, and (viii) the current status of the scheme and plans for its effective implementation.
Asunto(s)
Contaminación del Aire , Monitoreo del Ambiente/normas , Administración de Residuos/normas , Residuos , Contaminación del Agua , Monitoreo del Ambiente/legislación & jurisprudencia , Agencias Gubernamentales , Guías como Asunto , Sustancias Peligrosas , India , Residuos Industriales , Capacitación en Servicio , Auditoría Administrativa/legislación & jurisprudencia , Control de Calidad , Administración de Residuos/legislación & jurisprudenciaRESUMEN
Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation. Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation. In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Gö-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 replication. Treatment of cells with PTX and Gö-6976 resulted in cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 replication. In addition, the combined use of anti-Tat sFv intrabodies and the two NF-kappa B inhibitors retained the virus in the latent state for as long as 45 days. The combined treatment resulted in more durable inhibition of HIV-1 replication than was seen with the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone. Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like the one reported here may improve the survival of transduced cells and prolong clinical benefit.
Asunto(s)
Fármacos Anti-VIH/farmacología , Carbazoles/farmacología , Productos del Gen tat/inmunología , Anticuerpos Anti-VIH/inmunología , VIH-1/efectos de los fármacos , Indoles/farmacología , FN-kappa B/antagonistas & inhibidores , Pentoxifilina/farmacología , Pirroles , Benzodiazepinas/farmacología , Linfocitos T CD4-Positivos , Línea Celular , Productos del Gen tat/metabolismo , Anticuerpos Anti-VIH/genética , Duplicado del Terminal Largo de VIH , VIH-1/fisiología , Humanos , Células Jurkat , Leucocitos Mononucleares , Fitohemaglutininas/farmacología , Factores de Tiempo , Activación Transcripcional , Transfección , Factor de Necrosis Tumoral alfa/farmacología , Replicación Viral/efectos de los fármacos , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
SUMMARY: Canventol (2-isopropyl-4-isopropyldencyclohex-2-ene-l-ol), a blocker of tumor necrosis factor alpha (TNF-alpha) release, inhibits human immunodeficiency virus type (HIV-1) production in chronically and acutely infected cells. This effect of Canventol on virus replication could be correlated with its inhibitory influence on necrosis factor (NF)-kappa B activation and HIV-1 long terminal repeat (LTR)-driven reporter gene expression in Jurkat cells and these could be overcome by the administration of TNF-alpha. Canventol inhibits activation of the promoter by the viral protein Tat through a TAR-independent mechanism. The HIV-1 promoter is synergistically upregulated when both the TAR-independent and the TAR-dependent modes of Tat action are in operation. Tat-induced downstream events, such as the production of cytokines like TNF-alpha and NF-kappa B activation, are central for this upregulation. Inhibitors of the respective modes of action of Tat downregulate HIV-1 LTR activation and virus replication.
Asunto(s)
Antivirales/farmacología , Ciclohexanoles/farmacología , Productos del Gen tat/fisiología , VIH-1/efectos de los fármacos , Pirroles , Replicación Viral/efectos de los fármacos , Antivirales/administración & dosificación , Secuencia de Bases , Benzodiazepinas/administración & dosificación , Línea Celular , Ciclohexanoles/administración & dosificación , Regulación hacia Abajo/efectos de los fármacos , Sinergismo Farmacológico , Productos del Gen tat/genética , Duplicado del Terminal Largo de VIH , VIH-1/genética , VIH-1/fisiología , Humanos , Datos de Secuencia Molecular , FN-kappa B/genética , Oligodesoxirribonucleótidos/genética , Regiones Promotoras Genéticas/efectos de los fármacos , Activación Transcripcional/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismo , Replicación Viral/genética , Replicación Viral/fisiología , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
The virus-encoded Tat protein strongly activates transcription of human immunodeficiency virus (HIV). A well-recognized mechanism involves interaction of Tat with the nascent RNA transcript of the viral tar gene; mutation of tar greatly decreases activation by Tat. However, Tat still provides a low level of activation, demonstrating that it also has a tar-independent mode of action. We propose that this tar-independent mode of Tat action is through activation of gene transcription to produce tumor necrosis factor alpha. This cytokine and other compounds that activate NF-kappa B up-regulate the HIV promoter at a low level, similarly to the second Tat action. Through this mechanism, they also activate promoters of tumor necrosis factor alpha and other cytokines and thereby establish an auto-up-regulatory loop. Activated NF-kappa B motifs in the HIV promoter synergize with Tat/tar. Mutations of these motifs decrease activation by Tat to a few percent of the wild-type value. In cooperation, the two modes of activation by Tat (tar dependent and cytokine based) set up positive up-regulatory loops which greatly superactivate transcription of HIV. Agents that block these synergistic pathways at three different steps and are more inhibitory in combination than is any one alone have been found. Thereby, multidrug modalities for transcription of HIV are proposed for virus suppression.
Asunto(s)
Citocinas/biosíntesis , Regulación Viral de la Expresión Génica , Productos del Gen tat/metabolismo , Duplicado del Terminal Largo de VIH , VIH-1/genética , Regiones Promotoras Genéticas , Secuencia de Bases , Línea Celular , Citocinas/metabolismo , Expresión Génica , Humanos , Interleucina-1/biosíntesis , Interleucina-6/biosíntesis , Cinética , Datos de Secuencia Molecular , Mutagénesis , FN-kappa B/metabolismo , Oligodesoxirribonucleótidos , ARN Viral/biosíntesis , ARN Viral/metabolismo , Transcripción Genética , Transfección , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/biosíntesis , Productos del Gen tat del Virus de la Inmunodeficiencia HumanaRESUMEN
BACKGROUND: This investigation deals with the molecular mechanism of anti-human immunodeficiency virus type 1 (HIV-1) action of pentoxifylline (PTX) [1-(5'-oxohexyl)-3, 7-dimethylxanthine] a drug widely used for the treatment of conditions involving defective regional microcirculation. MATERIALS AND METHODS: The inhibition by PTX of protein kinase C (PKC) or cAMP-dependent protein kinase (PKA)-mediated activation by phorbol ester (PMA) and tumor necrosis factor alpha (TNF-alpha) of HIV-1-LTR-regulated reporter gene expression was studied in human CD4+ T lymphocytes (Jurkat) and human embryo kidney cells (293-27-2). A protein kinase C is involved in activation of NF-kappa B in whole cells, identified by using inhibitors specific for PKC- or PKA-catalyzed NF-kappa B activation in whole cell and cell-free systems. RESULTS: PTX inhibited PKC- or PKA-catalyzed activation of NF-kappa B in cytoplasmic extracts from unstimulated Jurkat or 293-27-2 cells, but not interaction of preactivated NF-kappa B with its motifs. Calphostin C, a specific inhibitor of PKC, inhibited NF-kappa B activation and HIV-1 LTR-driven reporter gene expression in both PMA- and TNF-alpha-treated cells. In contrast, although H88 specifically inhibited PKA activity in the cell-free extract, it did not affect NF-kappa B action in PMA- or TNF-alpha-treated cells. CONCLUSIONS: The mechanism of inhibitory action of PTX on virus replication and NF-kappa B-induced transactivation of HIV-1 gene expression has been elucidated as due to blocking PKC-dependent PMA- or TNF-alpha-induced activation of NF-kappa B in Jurkat and 293-27-2 cells. Other protein kinase inhibitors may be useful in down regulating transcription of HIV-1 provirus and thereby virus replication in HIV-infected patients.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Duplicado del Terminal Largo de VIH/fisiología , FN-kappa B/metabolismo , Pentoxifilina/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Proteínas Quinasas Dependientes de AMP Cíclico/efectos de los fármacos , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Regulación hacia Abajo , Activación Enzimática/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica , Duplicado del Terminal Largo de VIH/efectos de los fármacos , Humanos , Naftalenos/farmacología , Pentoxifilina/metabolismo , Ésteres del Forbol/farmacología , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
No curative drug against HIV has yet been found, despite enormous efforts aimed at reverse transcriptase and a variety of other targets. The long terminal repeat (LTR) of HIV-1 has recently become a promising site for antiviral action. This article briefly summarizes information on the nature of this target and potential anti-LTR expression drugs.